Abstract:The synergistic advantage of combining tissue plasminogen activator (tPA) with pro-urokinase (proUK) for thrombolysis has been demonstrated in several in vitro experiments, and a single site proUK mutant ( m -proUK) has been developed for better stability in plasma. Based on these studies, combination thrombolytic therapy with intravenous tPA and m -proUK has been suggested as a promising treatment for patients with ischemic stroke. This paper evaluates the efficacy and safety of the dual therapy by computational simulations of pharmacokinetics and pharmacodynamics coupled with a local fibrinolysis model. Seven dose regimens are simulated and compared with the standard intravenous tPA monotherapy. Our simulation results provide more insights into the complementary reaction mechanisms of tPA and m -proUK during clot lysis and demonstrate that the dual therapy can achieve a similar recanalization time (about 50 min) to tPA monotherapy, while keeping the circulating fibrinogen level within a normal range. Specifically, our results show that for all dual therapies with a 5 mg tPA bolus, the plasma concentration of fibrinogen remains stable at around 7.5 μM after a slow depletion over 50 min, whereas a rapid depletion of circulating fibrinogen (to 5 μM) is observed with the standard tPA therapy, indicating the potential advantage of dual therapy in reducing the risk of intracranial hemorrhage. Through simulations of varying dose combinations, it has been found that increasing tPA bolus can significantly affect fibrinogen level but only moderately improves recanalization time. Conversely, m -proUK doses and infusion duration exhibit a mild impact on fibrinogen level but significantly affect recanalization time. Therefore, future optimization of dose regimen should focus on limiting the tPA bolus while adjusting m -proUK dosage and infusion rate. Such adjustments could potentially maximize the therapeutic advantages of this combination therapy for ischemic stroke treatment.

Amino-Fucoidan as a Vector for rtPA-Induced Fibrinolysis in Experimental Thrombotic Events

Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke

Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots

Engineered microparticles and nanoparticles for fibrinolysis

Rationale and Design of Combination of an Immune Modulator Fingolimod with Alteplase Bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) Trial.

Harnessing micrometer-scale tPA beads for high plasmin flux and accelerated fibrinolysis

Alleviating Recombinant Tissue Plasminogen Activator-induced Hemorrhagic Transformation in Ischemic Stroke via Targeted Delivery of a Ferroptosis Inhibitor

A triple fusion tissue-type plasminogen activator (TriF-ΔtPA) enhanced thrombolysis in carotid embolism-induced stroke model

Delivery Of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein To The Cerebral Vasculature Lyses Arterial Clots And Attenuates Postischemic Brain Edema

R-tPA Resistance Is Specific for Platelet-Rich Stroke Thrombi and Can Be Overcome by Targeting Nonfibrin Components

Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy

Endothelial Targeting of a Recombinant Construct Fusing a PECAM-1 Single-Chain Variable Antibody Fragment (scfv) with Prourokinase Facilitates Prophylactic Thrombolysis in the Pulmonary Vasculature

Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.

Targeted Thrombolysis by Using C-Rgd-modified N,N,N-Trimethyl Chitosan Nanoparticles Loaded with Lumbrokinase

In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke

Targeting of A Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis

Fibrin Degradation During Sonothrombolysis – Effect of Ultrasound, Microbubbles and Tissue Plasminogen Activator

Targeted thrombolysis by magnetoacoustic particles in photothrombotic stroke model

In-vivo thrombolytic efficacy of RGD modified protein-polymer conjugated urokinase nanogels